Koshinski Asset Management Inc. Acquires 322 Shares of AstraZeneca PLC (NASDAQ:AZN)

Koshinski Asset Management Inc. increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,933 shares of the company’s stock after acquiring an additional 322 shares during the period. Koshinski Asset Management Inc.’s holdings in AstraZeneca were worth $454,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. McClarren Financial Advisors Inc. increased its holdings in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares during the period. Capital Performance Advisors LLP bought a new stake in AstraZeneca during the 3rd quarter worth approximately $28,000. Ashton Thomas Securities LLC bought a new stake in AstraZeneca during the 3rd quarter worth approximately $45,000. Hollencrest Capital Management increased its holdings in AstraZeneca by 38.4% during the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock worth $54,000 after acquiring an additional 192 shares during the period. Finally, Versant Capital Management Inc increased its holdings in AstraZeneca by 2,618.5% during the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after acquiring an additional 707 shares during the period. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, AstraZeneca has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at $68.20 on Thursday. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The stock has a market capitalization of $211.49 billion, a price-to-earnings ratio of 32.63, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46. The company has a fifty day moving average of $66.20 and a 200-day moving average of $74.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the company earned $0.87 EPS. The firm’s revenue was up 18.0% on a year-over-year basis. Equities research analysts expect that AstraZeneca PLC will post 4.12 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.